Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel

Abstract

High stathmin expression predicted an unfavorable prognosis in patients with ovarian cancer who received paclitaxel and platinum chemotherapy. This finding supports the possibility that stathmin may interfere with paclitaxel treatment, leading to a poor prognosis for patients with ovarian cancer.